References

  1. Kearney P, Whelton M, Reynolds Kristi, Muntner P, Whelton P, He J .Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15;365(9455):217-23. PubMed | Google Scholar

  2. Ministère de la sante. Enquête nationale sur les facteurs de risque cardiovasculaire. 2001. Ministère de la santé. Maroc. PubMed | Google Scholar

  3. Prospective studies collaboration. Age specific relevance of usual blood pressure to vascular mortality: a meta-analyse of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-1913. PubMed | Google Scholar

  4. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.Lancet.2004 Sept 11;364(9438):937-52. PubMed | Google Scholar

  5. Klag MJ, Whelton PK, Randall BL, Neaton JD, Klag FL et al. Blood pressure and end-stage renal disease in men. N engl j Med.1996 Jan 4;334(1):13-18. PubMed | Google Scholar

  6. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J. 1976;2(6035):554-6. PubMed | Google Scholar

  7. Lewin A, Blaufox D, Castle H, Entwisle G, Langford H. Apparent prevalence of curable hypertension in the hypertension detection and follow-up programme. Arch Intern Med. 1985;145(3):424-7. PubMed | Google Scholar

  8. Saito O, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Research. 2004;27(3):193-202. PubMed | Google Scholar

  9. Mathonnet M. Conduite à tenir face à un incidentalome surrénalien associé à une hypertension artérielle. Annales de chirurgie. 2005 Jun;130(5):303-308. PubMed | Google Scholar

  10. Amar L, Lepoutre C, Bobrie G, Plouin P-F. Hypertension artérielle endocrine. La Revue de médecine interne. 2010 Oct;31(10):697-704. PubMed | Google Scholar

  11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. National Heart and lung, and blood institute : National high Blood Pressure Education Program Coordinationg committee. Seventh report of the joint National Committee on Prevention, Detection, Evaluation, and treatment of high Blood Pressure. Hypertension. 2003;42:1206-1252. PubMed | Google Scholar

  12. ESH-ESC. Recommandations 2007 ESH-ESC pour la prise en charge de l'hypertension artérielle. Traduit de Journal of Hypertension. 2007; 25 : 1105-87. PubMed | Google Scholar

  13. Baudin B, Berthelot-Garcias E, Meuleman C, Dufaitre G, Ederhy S, Haddour N et al. Biologie de l'hypertension artérielle. Marqueurs biochimiques des maladies cardiovasculaires. Revue francophone des les laboratoires. 2009 Feb; 2009(409):27-39. PubMed | Google Scholar

  14. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an Increased Rate of Cardiovascular Events in Patients With Primary Aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. PubMed | Google Scholar

  15. Calhoun DA, Jones D, Textor S, Goff DC., Murphy TP, Toto RD, White A et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-26. PubMed | Google Scholar

  16. Girerd X, Rosenbaum D, Villeneuve F. Hypertension artérielle résistante : stratification de la prise en charge. Presse Med. 2009 April;38(4):643-651. PubMed | Google Scholar

  17. Sarafidis P, Bakris G. Resistant hypertension : an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749-57. PubMed | Google Scholar

  18. Giacchetti G, Turchi F, Boscaro M and Ronconi V. Management of primary aldosteronism: its complications and their outcomes after treatment. Curr Vasc Pharmacol. 2009;7(2):244-49. PubMed | Google Scholar

  19. Rossi GP, Bernini G,Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol.2006;48(11):2293-300. PubMed | Google Scholar

  20. De la Sierra A, Segura J, Banegas JR, Gorostidi M, De la Cruz JJ, Armario P et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the basis of Ambulatory Blood Pressure Monitoring. Hypertension. 2011 Mar 28;57(5);898-902. PubMed | Google Scholar

  21. Mulatero P, Stowasser M, LohKeh C, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004 Jul 2;89(3):1045-50. PubMed | Google Scholar

  22. Herpin D, Sosner P, Chamontin B. Investigation of hyperaldosteronism in the hypertensive patient. Why' When' How'. Arch Mal Coeur Vaiss. 2003;96(1):37-42. PubMed | Google Scholar

  23. Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K. et al. Adrenal Venous Sampling: Evaluation of the German Conn's Registry. Hypertension. 2011 Mar 7;57;990-995. PubMed | Google Scholar

  24. Vallotton MB. Primary aldosteronism. Diagnosis of primary Hyperaldosteronism. Clinical Endocrinology. 1996 Oct 13;45(1):47-52. PubMed | Google Scholar

  25. Maiter D. L'hyperaldostéronisme primaire : une cause fréquente d'hypertension artérielle. Louvain médical. 2007;126(3):S14-20. PubMed | Google Scholar

  26. Bravo EL. Pheochromocytoma: an approach to antihypertensive management. Ann N Y Acad Sci. 2002 Jan 24;970(1): 1749-6632. PubMed | Google Scholar

  27. Bravo EL. Pheochromocytoma. Cardiology in review. 2002 Jan;10(1):44-5. PubMed | Google Scholar

  28. Mannelli M, Ianni L, Cilotti A, conti A. Pheochromocytoma in Italy: a multicentricretrospective study. Eur J Endocrinol. 1999 December 1;141(6):619-624. PubMed | Google Scholar

  29. Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009 Jul 4;161(2):355-361. PubMed | Google Scholar

  30. Plouin PF, Duclos JM, Soppelsa F, Boublil G, and Chatellier G et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. Jcem. 2013 Jul 2; 86(4):1480-1488. PubMed | Google Scholar

  31. Walther McM, Herring J, Enquist E, Keiser HR et al. Von Recklinghausen's disease and pheochromocytomas. J Urol.1999 Nov;162(5):1582-6. PubMed | Google Scholar

  32. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005 Dec 1;23(34):8812-8. PubMed | Google Scholar

  33. Magiakou MA, Smyrnaki P, Chrousos G. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2006 Sept;20(3):467-82. PubMed | Google Scholar

  34. Cicala Maria Verena, Mantero Francesco. Hypertension in Cushing's syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92(Suppl 1):44-9. PubMed | Google Scholar

  35. Mancini T, Kola B, Mantero F, Boscaro M et al. High cardiovascular risk in patients with Cushing'ssyndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology. 2004 Dec 3; 61(6):768-777. PubMed | Google Scholar

  36. Selvais PL, Donckier JE et al. Tableau Clinique actuel de la maladie de Cushing. Louvain Med. 1997;116(8):293-299. PubMed | Google Scholar

  37. Kasik Valette S. Facteurs prédictifs de guérison de la Maladie de Cushing après chirurgie hypophysaire. Rev fr endocrinol Clin.1999;40(3-5):317-325. PubMed | Google Scholar

  38. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clinical Endocrinology. 2005 Sept 3;63(4):470-476. PubMed | Google Scholar

  39. Bex M, Abs R, Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D. AcroBel ' the Belgian registry on acromegaly: a survey of the "real-life" outcome in 418 acromegalic subjects. European Journal of Endocrinology.2007; 157(4):399-409. PubMed | Google Scholar

  40. Colao AM, Terzolo M, Bondanelli a, Galderezi M, Vitale G et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf). 2008 April 10 ;69(4):613-20. PubMed | Google Scholar